NEW YORK (GenomeWeb News) – BiOasis said today that it has tapped the Anderson Forschung Group to develop a new proteomics assay for diagnosing Alzheimer’s disease.
Under the agreement, Anderson Forschung will develop an assay using a technique called Stable Isotope Standards and Capture by Anti-Peptide Antibodies, a proteomics platform aimed at biomarker quantification and qualification.
The SISCAPA technique was developed to measure protein levels in human plasma and is based on immunoaffinity enrichment of peptide surrogates of biomarker proteins and their identification by mass spectrometry.
The company said that the technique improves standard immunoassays because the analytes are identified by mass spectrometry, the assay detects peptide surrogates rather than protein targets, allowing for less variability due to degradation, and it is less subject to interference caused by antibodies that bind the analyte because those are destroyed during the sample preparation step.
BiOasis, based in Surrey, BC, will use SISCAPA as a second, independent method for quantification of p97 in human plasma in parallel with a sandwich immunoassay, which could add confidence for qualification of the biomarker for Alzheimer’s disease.
Financial terms of the agreement were not released.
Leigh Anderson, the founder of Anderson Forschung, is a member of BiOasis's scientific advisory board.